• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Plasmacytoid DC engagement by Flu vaccine as a surrogate strategy for driving Th1 responses in human neonatal settings

tetano

Editor, Senior Moderator
J Infect Dis. 2014 Feb 20. [Epub ahead of print]
Plasmacytoid DC engagement by Flu vaccine as a surrogate strategy for driving Th1 responses in human neonatal settings.
Zhang X1, Casartelli N, Lemoine S, Mozeleski B, Azria E, Le Ray C, Schwartz O, Launay O, Leclerc C, Lo-Man R.
Author information
Abstract

Background. The elicitation of Th1 cellular immunity to eradicate intracellular pathogens is a challenging task due to the IL-12 deficit observed in early infancy.Methods. Screening cord blood responses to various pediatric vaccines and TLR agonists for innate responses and CD4 T cell differentiation.Results. We identified that non-adjuvanted inactivated trivalent influenza vaccine (TIV) was able to cosignal T cells for the production of IFN-g in a neonatal setting. This process includes the mobilization of neonatal plasmacytoid dendritic cells (pDC) as antigen-presenting cells (APC) that efficiently engage Th1 cells in an IL-12-independent, but type I interferon-dependent manner. In addition, cord blood pDCs efficiently cross-presented antigen to CD8 T cells. Importantly, activation by TIV mainly requires TLR7; however, R848/TLR7 and CpGB/TLR9 activated pDCs which poorly produced IFN-α induce neonatal Th2 responses.Conclusions. TLR pathway engagement in pDCs is necessary but not sufficient for a successful neonatal Th1 outcome. We provide evidence of a mature and functional neonatal immune system at the level of APCs and T cells and propose to implement the IFN-a/IFN-g axis in pediatric vaccination as a surrogate for the defective IL-12/IFN-g axis.

PMID:
24558121
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24558121
 
Back
Top Bottom